Substantial EU Funding to International BOUNCE Consortium
The goal of the project is to support value based healthcare. In practical terms, this means the development of cost-efficient clinical tools for patient empowerment and for enhancing patients’ capacity to recover from cancer treatments.
The BOUNCE Consortium includes experts in the fields of oncology, computer modeling, psychology, and social medicine from Finland, Greece, Italy, Portugal, and Israel. Helsinki University Hospital Comprehensive Cancer Center has been chosen to coordinate this prospective, multi-center study on how to optimally support breast cancer patients and improve their resilience. BOUNCE received a five-million-euro funding and near perfect score at the evaluation stage, attesting to its expected impact. It is a four-year project which started in November 2017.
Breast cancer is the most common cancer in women worldwide. More than half of breast cancer patients are actively working. Good quality of life and ability to return to normal life after cancer diagnosis are important to patients.
The BOUNCE project will explore factors that influence breast cancer patients’ resilience over a two-year period, and will address their capacity to resume a normal everyday life and work following breast cancer treatments. Resilience experts will initially develop a working model of resilience to breast cancer and of related clinical, biological, social, and psychological factors. This model will be tested in a prospective multicenter study that will recruit large numbers of early phase breast cancer patients from specialized cancer treatment centers in Finland, Israel, Italy, and Portugal.
The wealth of patient information targeted by BOUNCE will be registered through innovative, interactive mobile solution designed by Noona Healthcare in close collaboration with its earlier research and development partner Helsinki University Hospital Comprehensive Cancer Center. Information technology experts will apply innovative computational tools to identify key factors involved in building and maintaining resilience in these women.
The BOUNCE Consortium includes: Helsinki University Hospital Comprehensive Cancer Center Finland, Foundation for Research and Technology -Hellas, Greece, European Institute of Oncology Italy, Institute of Communication and Computer Systems Greece, NHG Consulting Finland, Hebrew University School of Social Work and Social Welfare Israel, Singularlogic S.A Greece, Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud (Champalimaud Clinical Center & Foundation Portugal, Noona Healthcare Finland.
The Hospital District of Helsinki and Uusimaa
Ms. Johanna Mattson, +358 50 427 9165
Director of Helsinki University Hospital Comprehensive Cancer Center
Ms. Paula Poikonen-Saksela, +358 50 427 0623
Project Coordinator, Helsinki University Hospital Comprehensive Cancer Center
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DE-INCYTE21.10.2018 12:47 | pressemeddelelse
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
SERVIER21.10.2018 11:12 | pressemeddelelse
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum